Friday, September 19, 2014
BioCryst Receives $20M to develop Ebola Treatment
Durham's Durham’s BioCryst Pharmaceuticals, Inc. received another $2 million to continue development of a possible Ebola virus treatment from the National Institute of Allergy and Infectious Diseases.
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment